Insmed CMO sells 1,887 shares under trading plan

Insmed Inc.'s Chief Medical Officer, Martina Flammer, reported a sale of company common stock.

Accepted by SEC EDGAR 01/13/2026 - 04:03 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Insmed Inc.'s Chief Medical Officer, Martina Flammer, reported a sale of company common stock. On January 9, 2026, she sold 1,887 shares of Insmed common stock at a price of $186.19 per share, as shown in Table I of the filing.

The filing states that this transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2025. After this sale, Flammer beneficially owns 84,907 shares of Insmed common stock, held directly.

Insider Trade Summary

Net Seller: 1,887 shares

Net Sell 1 txn

Insider Flammer Martina M.D.

Role Chief Medical Officer

Sold 1,887 shs ($351K)

Share of Position Sold 2.2%

Type	Security	Shares	Price	Value
Sale	Common Stock	1,887	$186.19	$351K

Holdings After Transaction: Common Stock — 84,907 shares (Direct)

Holdings Before and After: Common Stock, 86,794 to 84,907 shares (Direct)

Other Insiders: 4 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Insmed (INSM) report in this Form 4?

The Form 4 shows that Insmed's Chief Medical Officer, Martina Flammer, sold 1,887 shares of Insmed common stock on January 9, 2026.

At what price were the Insmed (INSM) shares sold by the CMO?

The filing reports that the 1,887 shares of Insmed common stock were sold at a price of $186.19 per share.

How many Insmed (INSM) shares does the CMO own after this sale?

Following the reported transaction, Chief Medical Officer Martina Flammer beneficially owns 84,907 shares of Insmed common stock, held directly.

Was the Insmed (INSM) insider sale made under a 10b5-1 trading plan?

Yes. The filing explains that the transaction was effected under a Rule 10b5-1 trading plan adopted by the reporting person on February 27, 2025.

What is the role of the reporting person in Insmed (INSM)?

The reporting person, Martina Flammer, M.D., is an officer of Insmed Inc., serving as its Chief Medical Officer.

Is this Insmed (INSM) Form 4 filed for a single reporting person?

Yes. The document indicates that the Form 4 is filed by one reporting person, namely Chief Medical Officer Martina Flammer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Flammer Martina M.D.

(Last) (First) (Middle)

700 US HIGHWAY 202/206

(Street)

BRIDGEWATER NJ 08807

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INSMED Inc [ INSM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/09/2026		S(1)		1,887	D	$186.19	84,907	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Remarks:

	/s/ Martina Flammer, M.D., by Michael A. Smith as Attorney-in-fact	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.